Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus treated in real‐world clinical practice: Results of a 36‐month post‐marketing surveillance study (J‐STEP/LT)

Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus treated in real‐world clinical practice: Results of a 36‐month post‐marketing surveillance study (J‐STEP/LT)

Abstract Aims/Introduction Tofogliflozin is a sodium–glucose cotransporter 2 (SGLT2) inhibitor that lowers plasma glucose levels by enhancing urinary glucose excretion. After its approval in Japan in 2014 for the treatment of type 2 diabetes mellitus, we carried out a 3‐year prospective observationa...

Full description

Bibliographic Details
Main Authors: Kazunori Utsunomiya, Ryusuke Koshida, Seigo Kakiuchi, Masayuki Senda, Shoko Fujii, Yuji Kurihara, Ryoji Gunji, Kohei Kaku
Format: Article
Language:English
Published: Wiley 2021-02-01
Series:Journal of Diabetes Investigation
Subjects:
Post‐marketing surveillance
Tofogliflozin
Type 2 diabetes mellitus
Online Access:https://doi.org/10.1111/jdi.13333

Internet

https://doi.org/10.1111/jdi.13333

Similar Items